HPTN 102/PURPOSE 3
Recruiting
18 years or above
Female
Phase
2
1 Location
Brief description of study
This study will test an experimental drug named Lenacapavir (LEN), also known as Sunlenca® for the prevention of HIV-1 infection. The other HIV and pre-exposure prophylaxis (PrEP) medication included in this study is F/TDF (brand name Truvada®) which contains emtricitabine (F) and tenofovir disoproxil fumarate (TDF). F/TDF is approved for PrEP for use in adults and adolescents weighing at least 35kg (about 77 pounds) by the FDA in United States. Lenacapavir (LEN) is currently approved by the Food and Drug Administration (FDA) in the United States, Health Canada in Canada, and the European Medicines Agency (EMA) in Europe for the treatment of human immunodeficiency virus (HIV) infection in heavily treatment experienced (HTE) adults with multi-drug resistant (MDR) HIV infection. LEN is currently not approved by FDA or other regulatory authorities for treatment in other HIV populations or for prevention of HIV. LEN is being studied in this study for possible use for prevention of HIV infection.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: HIV Negative
-
Age: 18 years or above
-
Gender: Female
Updated on
13 Dec 2024.
Study ID: 854195
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
